Risk-Based Approach To Clinical AE Reporting Needed – Medtronic’s Westrum
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial sponsors are limited in their ability to facilitate compliance with institutional review boards, even though investigators often lack thorough grounding in IRB policies, according to Medtronic Director of Clinical Affairs Barbara Westrum
You may also be interested in...
FDA Eyes Changes To IRB Adverse Event Reporting; March Meeting Planned
Device manufacturers and other stakeholders will have an opportunity next month to discuss ways that reporting adverse events to institutional review boards can be improved
FDA Eyes Changes To IRB Adverse Event Reporting; March Meeting Planned
Device manufacturers and other stakeholders will have an opportunity next month to discuss ways that reporting adverse events to institutional review boards can be improved
Data Safety Monitoring Board Guidance To Provide Rules For Halting Trials
FDA's draft guidance on data safety monitoring boards (DSMBs) will address when clinical trials should be stopped for safety or efficacy reasons.